Literature DB >> 12875961

Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology.

Gabor Méhes1, Andrea Luegmayr, Rosa Kornmüller, Ingeborg M Ambros, Ruth Ladenstein, Helmut Gadner, Peter F Ambros.   

Abstract

The sensitive detection of bone marrow involvement is crucial for tumor staging at diagnosis and for monitoring of the therapeutic response in the patient's follow-up. In neuroblastoma, only conventional cytomorphological techniques are presently accepted for the detection of bone marrow involvement, yet since the therapeutic consequences of the bone marrow findings may be far-reaching, the need for highly reliable detection methods has become evident. For this purpose, we developed an automatic immunofluorescence plus FISH (AIPF) device which allows the exact quantification of disseminated tumor cells and the genetic verification in critical cases. In this study, the power of the immunofluorescence technique is compared with conventional cytomorphology. 198 samples from 23 neuroblastoma patients (stages 4 and 4s) at diagnosis and during follow-up were investigated. At diagnosis, 45.6% of the samples (26 of 57) which were positive by AIPF investigation were negative by cytomorphology. During follow-up, 74.2% (49 of 66) of AIPF-positive samples showed no cytological signs of tumor cell involvement. False negative morphological results were found in up to 10% of tumor cell content. A tumor cell infiltrate below 0.1% was virtually not detectable by conventional cytomorphology. Using the sensitive immunofluorescence technique, the analysis of only two instead of four puncture sites did not lead to false negative results. Thus, the immunofluorescence technique offers an excellent tool for reliable detection and quantification of disseminated tumor cells at diagnosis and during the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12875961      PMCID: PMC1868212          DOI: 10.1016/S0002-9440(10)63669-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?

Authors:  N K Cheung; G Heller; B H Kushner; C Liu; I Y Cheung
Journal:  J Clin Oncol       Date:  1997-08       Impact factor: 44.544

2.  Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.

Authors:  I Funke; W Schraut
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies.

Authors:  N K Cheung; D D Von Hoff; S E Strandjord; P F Coccia
Journal:  J Clin Oncol       Date:  1986-03       Impact factor: 44.544

4.  A hypervariable repeated sequence on human chromosome 1p36.

Authors:  N Buroker; R Bestwick; G Haight; R E Magenis; M Litt
Journal:  Hum Genet       Date:  1987-10       Impact factor: 4.132

5.  Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines.

Authors:  P F Ambros; I M Ambros
Journal:  Med Pediatr Oncol       Date:  2001-12

6.  Detection of bone marrow infiltration by neuroblastoma in clinical practice: how far have we come?

Authors:  M M Reid
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

7.  Cloning of human satellite III DNA: different components are on different chromosomes.

Authors:  H J Cooke; J Hindley
Journal:  Nucleic Acids Res       Date:  1979-07-25       Impact factor: 16.971

8.  Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.

Authors:  K Mujoo; T J Kipps; H M Yang; D A Cheresh; U Wargalla; D J Sander; R A Reisfeld
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

9.  Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA.

Authors:  S A Burchill; F M Bradbury; P Selby; I J Lewis
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

10.  Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA.

Authors:  Y Miyajima; K Horibe; M Fukuda; K Matsumoto; S Numata; H Mori; K Kato
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

View more
  9 in total

Review 1.  Micrometastases in neuroblastoma: are they clinically important?

Authors:  S A Burchill
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

Review 2.  Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Julie R Park; Rochelle Bagatell; Susan L Cohn; Andrew D Pearson; Judith G Villablanca; Frank Berthold; Susan Burchill; Ariane Boubaker; Kieran McHugh; Jed G Nuchtern; Wendy B London; Nita L Seibel; O Wolf Lindwasser; John M Maris; Penelope Brock; Gudrun Schleiermacher; Ruth Ladenstein; Katherine K Matthay; Dominique Valteau-Couanet
Journal:  J Clin Oncol       Date:  2017-05-04       Impact factor: 44.544

3.  Clinico-epidemiology of neuroblastoma in north east Egypt: A 5-year multicenter study.

Authors:  Youssef Al-Tonbary; Mohamed Badr; Ahmed Mansour; Usama El Safy; Shebl Saeed; Tamer Hassan; Rasha Elashery; Rofida Nofal; Ahmad Darwish
Journal:  Oncol Lett       Date:  2015-06-08       Impact factor: 2.967

4.  Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow.

Authors:  Katrien Swerts; Peter F Ambros; Chantal Brouzes; José M Fernandez Navarro; Nicole Gross; Dyanne Rampling; Roswitha Schumacher-Kuckelkorn; Angela R Sementa; Ruth Ladenstein; Klaus Beiske
Journal:  J Histochem Cytochem       Date:  2005-06-13       Impact factor: 2.479

5.  The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.

Authors:  Dominik Bogen; Clemens Brunner; Diana Walder; Andrea Ziegler; Reza Abbasi; Ruth L Ladenstein; Rosa Noguera; Tommy Martinsson; Gabriele Amann; Freimut H Schilling; Marek Ussowicz; Martin Benesch; Peter F Ambros; Inge M Ambros
Journal:  Int J Cancer       Date:  2016-03-22       Impact factor: 7.396

6.  Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma.

Authors:  Felix Schriegel; Sabine Taschner-Mandl; Marie Bernkopf; Uwe Grunwald; Nikolai Siebert; Peter F Ambros; Inge Ambros; Holger N Lode; Guenter Henze; Karoline Ehlert
Journal:  J Cancer Res Clin Oncol       Date:  2021-10-08       Impact factor: 4.322

7.  An annotated fluorescence image dataset for training nuclear segmentation methods.

Authors:  Florian Kromp; Eva Bozsaky; Fikret Rifatbegovic; Lukas Fischer; Magdalena Ambros; Maria Berneder; Tamara Weiss; Daria Lazic; Wolfgang Dörr; Allan Hanbury; Klaus Beiske; Peter F Ambros; Inge M Ambros; Sabine Taschner-Mandl
Journal:  Sci Data       Date:  2020-08-11       Impact factor: 6.444

8.  Landscape of Bone Marrow Metastasis in Human Neuroblastoma Unraveled by Transcriptomics and Deep Multiplex Imaging.

Authors:  Daria Lazic; Florian Kromp; Fikret Rifatbegovic; Peter Repiscak; Michael Kirr; Filip Mivalt; Florian Halbritter; Marie Bernkopf; Andrea Bileck; Marek Ussowicz; Inge M Ambros; Peter F Ambros; Christopher Gerner; Ruth Ladenstein; Christian Ostalecki; Sabine Taschner-Mandl
Journal:  Cancers (Basel)       Date:  2021-08-26       Impact factor: 6.639

9.  Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma.

Authors:  Vinod Vijay Subhash; Libby Huang; Alvin Kamili; Marie Wong; Dan Chen; Nicola C Venn; Caroline Atkinson; Chelsea Mayoh; Pooja Venkat; Vanessa Tyrrell; Glenn M Marshall; Mark J Cowley; Paul G Ekert; Murray D Norris; Michelle Haber; Michelle J Henderson; Rosemary Sutton; Jamie I Fletcher; Toby N Trahair
Journal:  Br J Cancer       Date:  2021-09-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.